Obstructive sleep apnea (OSA) has long been defined by slow, incremental progress—better masks, smarter PAP algorithms, and small improvements in surgical techniques and workflow. But 2026 is shaping up to be very different. For the first time, multiple forces across pharmacology, surgical devices, and tech at large are converging to redefine OSA care.
Here are the biggest storylines to watch this year:
1. The Hypoglossal Nerve Stimulation (HGNS) Era Becomes a Three-Way Race
For most of the last decade, Inspire operated with little direct competition.
That era is over.
Three companies will dominate the conversation in 2026:
Inspire – the incumbent under pressure
Will their growth maintain with two new competitor surgeries in the US?
Inspire V technology and improved sensing & titration tools now standard
Nyxoah – the bilateral challenger starting its launch
U.S. commercial launch has started, to expand widely in 2026.
LivaNova – the neuromodulation veteran entering with pHGNS
Proximal cuff design with selective stimulation
Strong OSPREY data (and PolySync software)
Why it matters:
For clinicians, this competition will hopefully enhance patient selection and outcomes. We are particularly excited with efforts to ease follow up and monitoring of HNS patients post-operatively.
2. Apnimed AD109 Introduces OSA Pharmacotherapy
For decades, “a pill for sleep apnea” was viewed as naïve at best, impossible at worst.
2026 is the year that assumption breaks.
Apnimed’s AD109 program (aroxybutynin + atomoxetine) is now in late-stage development, with Phase 3 data showing meaningful OSA impact.
Thus far, efficacy appears solid and side effects manageable, 2026 should expand the early data. Hopefully, we can get a better idea of who ‘best’ responds to this therapy, and where it could fit into OSA workflows heading into likely 2027 approval.
Why it matters:
Pharmacologic therapy would fundamentally broaden the treatment options. Novel respiratory stabilizer and nasal sprays are also in the pipeline.
3. GLP-1 Medications Become Part of the OSA Workflow
2025 was the year GLP-1s entered the sleep medicine vocabulary.
2026 is the year they become standard part of the workflow.
This creates a new practice pattern, for obese OSA patients:
GLP-1 + CPAP vs. GLP-1 for those refusing CPAP.
Sleep specialists will need to define when weight loss is first-line, how it intersects with device therapy, and which patient profiles respond best.
Why it matters:
GLP-1s are reshaping obesity, metabolic health, and now sleep. The specialty must own this conversation or risk being sidelined.
4. The Next Generation of Neurostimulation: New Targets, New Approaches
OSA stimulation is no longer a one-nerve game. New targets and less-invasive/miniaturized delivery techniques are heading toward trial.
We’re entering the next era of neurostimulation. A couple we’re watching:
Lunair (Phrenic nerve)
Stimaire
We look forward to sharing progress on new companies helping to improve OSA/snoring, advance the technology, and enhance outcomes/patient-safety.
5. Diagnostics and Access: The New Bottleneck
With demand skyrocketing and new therapies arriving, the weakest link in OSA care is increasingly:
delayed diagnostics for those who would benefit the most: underserved populations
PAP gatekeeping
workflow inefficiency
shortage of sleep specialists
Startups and incumbents are attacking this:
Wearable integrated diagnostics
AI-augmented HST interpretation
Faster care pathways (Telehealth OSA support, integrated dental/ENT/sleep models)
Why it matters:
Therapies mean nothing if patients never reach them. 2026 could be the year the industry finally acknowledges that diagnosis—not technology—is the fundamental bottleneck.
6. Phenotyping, Hypoxic Burden & the Push Toward Precision Sleep Medicine
One of the quiet but most important transformations happening in OSA is the shift away from treating AHI as the sole compass for diagnosis, severity, and follow-up.
2026 will accelerate adoption of physiologic phenotyping and risk-based assessment, anchored around metrics that matter more for long-term health outcomes.
Multiple studies continue to show that hypoxic burden—a measurement of cumulative oxygen desaturation load—is more predictive of cardiovascular and metabolic outcomes than AHI alone.
Expect broader use in:
OSA risk stratification
prioritizing treatment urgency
assessing residual risk in “treated” patients
evaluating therapy response beyond the sleep lab
7. Wearables Enter the Sleep Apnea Pipeline — And Will Drive More New Patients
2026 is the year consumer wearables officially become part of the OSA detection and referral engine. What began as “sleep tracking curiosity” is evolving into regulated, FDA-cleared early-alert systems.
With Apple Watch, Samsung, Oura Ring, and WHOOP now incorporating validated nocturnal desaturation alerts, irregular breathing metrics, and OSA risk notifications, millions of users are suddenly being told—directly on their wrist or phone—that they may have sleep apnea.
Final Take: 2026 Is Another Exciting Year in OSA Care
More patients being diagnosed, growing nuance to diagnostic discussions, and a burgeoning treatment armamentarium are all major storylines. We’ll continue to track each of these themes closely here. As always, we look forward to sharing and hearing from our audience. Thanks for making this an awesome first year of the newsletter.
Best, Chris & Robson.
How about Incannex Healthcare Inc with their IHL-42X for OSA ?